Evidence map›Paper›PMID 42325865›Full record

ArticleEuropean heart journal. Imaging methods and practice2026

Intra-coronary imaging and transcriptomics of calcified nodules before and after intensive lipid-lowering therapy: a YELLOW III substudy.

Pruthvi C Revaiah, Yuliya Vengrenyuk, JiaJia Liu, Keisuke Yasumura, Vemuri Krishna Santosh, Monika Karki, Ishani Bansal, Amit Hooda, Joseph K Sweeny, Sahil Khera and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Pruthvi C RevaiahDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Yuliya VengrenyukDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
JiaJia LiuUniversity of Texas Health Sciences Center, Houston, TX, USA.
Keisuke YasumuraDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Vemuri Krishna SantoshDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Monika KarkiDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Ishani BansalDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Amit HoodaDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.ORCID https://orcid.org/0000-0001-5659-5873
Joseph K SweenyDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Sahil KheraDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Vishal KapurDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Prakash KrishnanDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Pedro R MorenoDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Roxana MehranDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.ORCID https://orcid.org/0000-0002-5546-262X
Xiaobo ZhouUniversity of Texas Health Sciences Center, Houston, TX, USA.
Jagat NarulaUniversity of Texas Health Sciences Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-0280-3996
Samin K SharmaDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
Annapoorna S KiniDivision of Interventional Cardiology, Ichan School of Medicine at Mount Sinai and Fuster Heart Hospital at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Calcified nodules (CNs) contribute to 3-5% of acute coronary syndromes (ACS). Identifying peri-calcific lipid-rich areas is challenging with conventional imaging but feasible using near-infrared spectroscopy (NIRS). This YELLOW III substudy investigated the impact of maximal lipid-lowering on CN morphology and lipid content over 26 weeks. Methods and results: Patients with stable CAD and lipid-rich, non-obstructive plaques (lipid arc >90°, FCT <120 µm on OCT) received Evolocumab (140 mg biweekly) plus maximally tolerated statins. Lesions were evaluated at baseline and 26 weeks using combined NIRS-IVUS and OCT. Exploratory endpoints were the maximum 4 mm lipid core burden index (LCBI) in segments containing CNs (maxLCBI Conclusion: Intensive lipid-lowering significantly reduces peri-calcific lipid burden without measurable short-term changes in CN morphology. The clinical implications of LCBI reduction in CNs warrant further investigation. Summary: Calcified nodules (CNs) are high-risk coronary features responsible for a significant portion of acute coronary syndromes, yet their response to intensive medical therapy remains poorly understood. This YELLOW III substudy utilized multi-modality intravascular imaging (NIRS-IVUS and OCT) to investigate the impact of 26 weeks of Evolocumab and maximally tolerated statins on CN morphology. In 43 patients with identified CNs, intensive lipid-lowering therapy led to a significant reduction in the maxLCBI

Indexed as

calcified nodulefibrous cap thickness (FCT)lipid core burden index (LCBI)near infrared spectroscopy-intravascular ultrasound (NIRS–IVUS)optical coherence tomography (OCT)transcriptomics

Identifiers

PMID42325865
PMCPMC13282941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.